Adhesions of uterus

Summary

Adhesions of uterus (MONDO:0001809) is a disease and 3 clinical trials. Top therapeutic interventions include remifentanil. A subtype of uterine disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adhesions of uterus
Mondo ID	MONDO:0001809
DOID	DOID:13812
SNOMED CT	361115000
UMLS	C0241593
MedGen	537073
Is cancer (heuristic)	no

Also known as: intrauterine synechiae

Disease family

This is a subtype of uterine disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › uterine disorder › adhesions of uterus

Related subtypes (20): pyometritis, endometrial disorder, female infertility of uterine origin, uterine inflammatory disease, chronic subinvolution of uterus, cervix disorder, uterine polyp, pelvic congestion syndrome, uterine inversion, placenta disorder, hemometra, parametritis, cordiform uterus, septate uterus, bicornuate uterus, uterine hypoplasia, agenesis and aplasia of uterine body, tumor of uterus, florid cystic endosalpingiosis of the uterus, pregnancy, cornual

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07034963	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Study on the Effective Dose and Safety of Esketamine in Hysteroscopic Surgery Under Monitored Anesthesia Care
NCT07230600	PHASE1	RECRUITING	AD-SVF Therapy for Refractory Endometrial Infertility
NCT04638855	Not specified	COMPLETED	The Efficacy and Safety of Medicurtain® in Patients With Hysteroscopy (Pivotal Study)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
REMIFENTANIL	4	1